Zobrazeno 1 - 10 of 46 pro vyhledávání: '"B S, Kramer"'
1
CANCER SCREENING
Autor: B S, Kramer, O W, Brawley
Publikováno v: Hematology/Oncology Clinics of North America. 14:831-848
Especially in the emotionally charged field of cancer screening, which can have substantial public health implications for large numbers of healthy, asymptomatic people, it is important to achieve strong levels of evidence before promulgating new scr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a474f50728b53cd0eff73a20f22d5476
https://doi.org/10.1016/s0889-8588(05)70314-2
Zobrazit plný text záznamu
4
Clinical oncology update: Prostate cancer
Autor: B. S. Kramer, P. C. Prorok, J. K. Gohagan
Publikováno v: European Journal of Cancer. 33:348-353
WHAT HATH PROSTATE CANCER SCREENING WROUGHT? THE AMERICAN medical community and public have recently embraced new technologies in prostate cancer screening. There was a steady linear rise in the incidence of prostate cancer from 1973 to 1986, a trend
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a41bed33e3fa55b649c0f35c9d84c9cb
https://doi.org/10.1016/s0959-8049(97)89004-1
Zobrazit plný text záznamu
5
Five-alpha-reductase Inhibitors for prostate cancer prevention
Autor: T J, Wilt, R, MacDonald, K, Hagerty, P, Schellhammer, B S, Kramer
Publikováno v: The Cochrane database of systematic reviews. (2)
Five-alpha-reductase inhibitors (5ARI) are frequently used to treat bothersome lower urinary tract symptoms associated with benign prostatic hyperplasia and male androgenic alopecia. They have potential as chemopreventive agents.We sought to estimate
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9801d8c41b3d98281e3f5615e90b3d81
https://pubmed.ncbi.nlm.nih.gov/18425978
Zobrazit plný text záznamu
8
The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States
Autor: J M, Legler, E J, Feuer, A L, Potosky, R M, Merrill, B S, Kramer
Publikováno v: Cancer causescontrol : CCC. 9(5)
Trends in first-time and later PSA procedure rates are ascertained using longitudinal data from a population-based cohort. These trends are compared to trends in prostate cancer incidence to determine the role of PSA in the recent decline in prostate
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7534f4eece38d79d8f986f116873bfd3
https://pubmed.ncbi.nlm.nih.gov/9934717
Zobrazit plný text záznamu
9
Phase III, large-scale chemoprevention trials. Approach to chemoprevention clinical trials and phase III clinical trial of tamoxifen as a chemopreventive for breast cancer--the US National Cancer Institute experience
Autor: B K, Dunn, B S, Kramer, L G, Ford
Publikováno v: Hematology/oncology clinics of North America. 12(5)
Clinical trials to evaluate interventions for cancer prevention are designed as early (phase I, IIa, and IIb) or late-phase studies. Whereas the former are small and generally rely on intermediate endpoint biomarkers of carcinogenesis, the latter are
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::489f7dc68228f69de04244d94be5a614
https://pubmed.ncbi.nlm.nih.gov/9888019
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje